About the Authors

Isidoro González-Álvaro

isidoro.ga@ser.es

Affiliation Rheumatology Department, Hospital Universitario la Princesa, IIS-IP, Madrid, Spain

Isabel Castrejón

Affiliation Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, United States of America

Ana M. Ortiz

Affiliation Rheumatology Department, Hospital Universitario la Princesa, IIS-IP, Madrid, Spain

Esther Toledano

Affiliation Rheumatology Department. Hospital Clínico San Carlos, IdISSC, Madrid, Spain

Santos Castañeda

Affiliation Rheumatology Department, Hospital Universitario la Princesa, IIS-IP, Madrid, Spain

Alberto García-Vadillo

Affiliation Rheumatology Department, Hospital Universitario la Princesa, IIS-IP, Madrid, Spain

Loreto Carmona

Affiliation Instituto de Salud Musculoesquelética, Madrid, Spain

EMECAR Study Group

Membership of the EMECAR study group is provided in the Acknowledgments.

Competing Interests

IG-A received support from unrestricted research projects funded by BMS, Roche and UCB; paid consulting and delivering of presentations for Abbvie, BMS, Lilly, Pfizer, Roche and UCB. IG-A and AMO are co-inventors of the patent “Prognostic method for autoimmune disorders through genotyping Vasoactive Intestinal Peptide variants” with International Application PCT/ES2015/070182 having a positive international search report. SC has received education support, travel grants, consultancy fees, honoraria for clinical trials and speakers' fees from the following pharmaceutical companies: Abbvie, Amgen, Bristol Myers Squibb, Celgene, Gebro Pharma, Lilly, MSD, Pfizer and Roche. In the last 5 years, S. Castañeda has also been supported by an unrestricted research grant from Pfizer. IC, ET, AG-V and LC have no conflict of interest in relation with the present study. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: IG-A IC LC. Data curation: IG-A AMO LC. Formal analysis: IG-A LC. Funding acquisition: IG-A. Investigation: IG-A LC AMO ET SC AG-V EMECAR. Visualization: IG-A IC AMO ET SC AG-V LC. Writing – original draft: IG-A. Writing – review & editing: IG-A IC AMO ET SC AG-V LC.